Marsthine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Marsthine

Marsthine is the trade name for a medicinal product featuring the active component Clemastine Fumarate. It is a synthetic single-ingredient drug classified as a first-generation H1-receptor antagonist, also known as a classical antihistamine. This pharmacological classification defines it as an ethanolamine derivative used to counteract the systemic effects of histamine released by the body during allergic responses, providing foundational relief for allergic manifestations.


Quick Facts: Marsthine (Clemastine Fumarate)

Property Description
Active ingredient Clemastine Fumarate
Form Tablet, Oral Solution (Syrup), Injectable Solution
Pharmacological class First-Generation H1-Antagonist
Common purpose Systemic relief of allergic symptoms
Origin Synthetic ethanolamine derivative

What Type of Medicine is Marsthine? (Classification and Origin)

Marsthine is an agent that belongs to the pharmacological group of Histamine H1 Antagonists. This medicine is chemically classified as a synthetic organic compound, specifically a benzhydryl ether group antihistaminic. The classification of Clemastine Fumarate as a first-generation antihistamine is determined by its molecular ability to readily cross the blood-brain barrier, which is a key pharmacological feature distinguishing it from newer agents. This action has been clinically recognized for decades to provide relief in allergic presentations. This class of drug is widely used to manage conditions stemming from histamine-mediated responses.

Composition and Available Forms of Marsthine (Presentation)

Marsthine is manufactured as a single-ingredient product, with the therapeutic activity supplied exclusively by the Clemastine Fumarate. The medicine is formulated for both oral administration and parenteral administration, allowing for flexible systemic delivery. For oral use, it is available as a conventional solid tablet and as an oral solution or syrup, often focusing on a pediatric target audience through the liquid formulation. For contexts requiring rapid or specialized delivery, Marsthine is also prepared as a sterile injectable solution contained within ampoules.

General Purpose: Relieving Allergic Response Symptoms

The general purpose of Marsthine is to provide systemic relief by interrupting the biological chain reaction that triggers allergic discomfort throughout the body. By competitively binding to and blocking histamine H1 receptor sites, the medicine addresses the root cause of these systemic symptoms. A typical, neutral use scenario involves taking the medication to relieve a systemic response to an allergen, such as pollen. The drug is fundamentally utilized to counter the effects of histamine release associated with allergic reactions.

What side effects are possible with Marsthine?

Possible Side Effects and Safety Information

Adverse reactions associated with Marsthine (Clemastine Fumarate) are formally categorized in regulatory documentation based on frequency and affected system-organ class. As a first-generation H1-antagonist, the safety profile is dominated by effects on the central nervous system (CNS) and anticholinergic activity.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Very Common / Common Sedation (drowsiness), Dizziness, Disturbed coordination.
Uncommon / Rare Headache, Dry mouth, Nausea, Tachycardia (rapid heartbeat), Skin rash.
Serious Adverse Reactions Officially documented rare, severe events include anaphylactic shock and convulsions (seizures).

Adverse effects are documented across various System-Organ Classes, notably Nervous System Disorders (e.g., fatigue, sleepiness, confusion) and Gastrointestinal Disorders (e.g., dry mouth, constipation). Effects related to its anticholinergic properties may include blurred vision and urinary retention.

Population-Specific and Contextual Safety

Official labels detail distinct safety considerations for certain populations. Older adults (approximately 60 years or older) are noted to be more susceptible to adverse reactions, including increased risks of dizziness, sedation, and hypotension (low blood pressure). In contrast, pediatric patients may experience a paradoxical excitation characterized by nervousness, restlessness, or insomnia.

The official safety information includes limitations concerning activities requiring mental alertness; the risk of impaired vigilance means the ability to drive or operate heavy machinery may be compromised. Furthermore, regulatory documents note that the intensity of sedation is often more pronounced at the beginning of treatment.

This structured safety profile is the basis by which government authorities define the medicine's documented risks, organizing events by frequency and system to provide a complete overview of potential outcomes.

Overdose and Emergency Response

Recognizing an Overdose

Marsthine is an opioid, and overdose is a serious, life-threatening medical emergency primarily involving severe Central Nervous System (CNS) and respiratory depression. An overdose can occur when too much of the medication is taken or when it is combined with other CNS depressants, such as alcohol or certain sedative-hypnotic drugs.

Urgent Signs to Watch For

Immediate medical attention is required if any of the following signs are observed, as they indicate a dangerous lack of oxygen and depressed vital function:

  • Unresponsiveness: The person cannot be woken up, even with loud shouting or a vigorous sternal rub.
  • Breathing Difficulties: Breathing is very slow, shallow, irregular, or has stopped completely. Gurgling or snoring sounds may be heard (often called a "death rattle").
  • Skin Color Change: Lips, fingernails, or skin appear blue, purple, or grayish/ashen.
  • Pinpoint Pupils: The pupils (black centers of the eyes) are extremely small.
  • Limp Body: The body is unusually flaccid and relaxed.

Required Emergency Steps

If an overdose is suspected, take immediate action:

  1. Call 911 (or local emergency services) immediately. Clearly state that the person is unresponsive and not breathing.
  2. Administer an opioid antagonist (e.g., naloxone) if available and you are trained. This medication is designed to temporarily reverse the effects of an opioid overdose.
  3. Stay with the person and monitor their condition until emergency medical help arrives. If an antagonist was administered, the person must be observed for a minimum of four hours, as the overdose symptoms may return after the medication wears off, especially with long-acting opioids.

Therapeutic Uses of Marsthine

What Marsthine Treats: Main Uses and Benefits

Marsthine is commonly used to help with the symptoms associated with allergic reactions and conditions, including hay fever and hives. The medication is relevant for easing these manifestations through its antihistaminic action.


Symptomatic Relief for Allergic Conditions

Marsthine is generally used for managing symptoms that interfere with daily functioning, applicable across conditions involving episodic or fluctuating manifestations such as allergic rhinitis (hay fever), urticaria (hives), and allergic conjunctivitis. It helps address the symptom cluster of upper respiratory and ocular discomforts, including persistent sneezing, runny nose (rhinorrhea), nasal stuffiness, as well as itchiness and watering of the eyes. This support helps ease the overall symptom burden, particularly during periods of heightened symptoms or following acute allergen exposure. The medication is also relevant for managing dermal allergic reactions, helping to address generalized pruritus (itching) and the swelling and welt formation often associated with these conditions. It is applied in clinical settings that involve unstable symptom patterns, offering symptomatic assistance when symptoms become momentarily overwhelming or interfere with routine activities.


Quick Fact: Support for Allergic Discomfort Symptoms Symptom Domain Relief Focus Clinical Context
Respiratory Sneezing, runny nose Seasonal or perennial rhinitis
Dermal Itching (pruritus), swelling Hives (urticaria), mild angioedema
Ocular Watering, itchiness Allergic conjunctivitis

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Status

Marsthine (Clemastine Fumarate) is permitted for use in adults and the pediatric population aged 6 through 12 years, based on established safety and efficacy profiles documented in official labeling. However, use is explicitly not established for children under six years of age.


Populations Contraindicated (Must Not Use)

Official regulatory information strictly contraindicates Marsthine use in the following populations:

  • Neonates and premature infants.
  • Nursing mothers, due to the higher risk of adverse reactions in infants.
  • Individuals with a known hypersensitivity to Clemastine Fumarate or chemically related antihistamines.
  • Patients currently receiving Monoamine Oxidase (MAO) inhibitor therapy.

Conditional Use and Restrictions (Use with Caution)

Regulatory documents stipulate that Marsthine must be used with caution in patients with certain pre-existing conditions, which can limit eligibility. These conditions include a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, hypertension, and cardiovascular disease. Caution is also advised in cases of narrow-angle glaucoma and conditions causing urinary or gastrointestinal obstruction (e.g., prostatic hypertrophy or stenosing peptic ulcer).

Pregnancy Status

Marsthine is classified by the FDA as Pregnancy Category B. It should be used during pregnancy only if clearly needed, as there are no adequate and well-controlled studies in pregnant women.

What should I know about interactions with other medicines?

The regulatory documentation for Marsthine (Clemastine Fumarate) defines its interaction profile primarily through pharmacodynamic mechanisms, focusing on additive or intensifying effects on the central nervous and anticholinergic systems. This profile establishes constraints that dictate mandatory restrictions or prohibitions.

Contraindicated Combinations

The co-administration of Marsthine with Monoamine Oxidase (MAO) Inhibitors is strictly contraindicated by regulatory authorities. This restriction applies to both concurrent use and use within 14 days of discontinuing MAO inhibitor therapy. This prohibition is based on the documented interaction in which MAO inhibitors are shown to prolong and intensify the anticholinergic effects of Marsthine.

Pharmacodynamic and Substance Interactions

Marsthine has additive effects when co-administered with alcohol and other Central Nervous System (CNS) depressant agents. This category includes medicinal products such as hypnotics, sedatives, and tranquilizers. The official outcome of these combined substances is Additive CNS depression. Due to this documented interaction, regulatory labeling advises against the concurrent consumption of alcoholic beverages.

No specific interactions that significantly modify plasma exposure (e.g., AUC or Cmax) or that mandate a specific time-separation window are documented in the official prescribing information.

Mechanism of Action

How Marsthine Works

Marsthine exerts its effects by engaging multiple molecular targets to modulate key physiological signaling pathways. The drug's action is defined by its ability to competitively block receptors associated with histamine and acetylcholine, impacting both central and peripheral nervous system activity.


Antagonism of Histamine Signaling

Marsthine acts as an antagonist by binding to the Histamine-1 ( H1) receptor on blood vessels and other tissues. This interaction attenuates the cascade of signaling events typically initiated by H1 receptor activation, which includes effects on vascular permeability and smooth muscle tone. This mechanism contributes to influencing local fluid dynamics by reducing histamine-mediated capillary leakage and altering the signaling dynamics associated with widespread H1 receptor activation.


Anticholinergic Activity

Marsthine also interacts with and blocks muscarinic acetylcholine receptors. This secondary mechanism targets the cholinergic system, which regulates glandular function. Modulation of this pathway leads to decreased glandular secretions in the respiratory and digestive tracts, contributing to altered physiological responses of the affected peripheral systems.


Central Nervous System Engagement

The drug's lipophilicity allows it to cross the blood-brain barrier and engage H1 receptors within the Central Nervous System (CNS). By altering this core signaling pattern in the brain, the drug leads to a lowered state of alertness and physiological modulation of wakefulness.

Dosage and Administration Information

Marsthine, featuring the active component Clemastine Fumarate, is administered exclusively through the oral route. The medicine is manufactured in two primary formats for systemic delivery: conventional solid tablets (available in 1.34 mg and 2.68 mg strengths) and an oral solution or syrup (0.67 mg per 5 mL).

The standard dosing regimen for adults and adolescents aged 12 years and older typically begins with 1.34 mg taken twice daily (every 12 hours). The medication is used on an intermittent, as-needed basis for symptomatic relief, consistent with an acute usage pattern, and is not generally intended for continuous long-term maintenance. While the dosage frequency may be increased, the total daily intake must not exceed the maximum clinical limit of 8.04 mg Clemastine Fumarate in a 24-hour period.

For the pediatric population aged 6 to 11 years, the regimen specifies a reduced maximum daily dose of 4.02 mg. When the liquid oral solution is administered, instructions require the use of a calibrated measuring device to ensure the dose is dispensed accurately. The use of lower doses may be warranted for older adults and for patients presenting with hepatic impairment, based on administration principles related to age and metabolic considerations.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Marsthine (Clemastine Fumarate)

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research explored Marsthine in studies examining patient-reported experiences related to allergic rhinitis symptoms, which includes common seasonal and perennial hay fever. Studies conducted for this purpose primarily used short-term Randomized Controlled Trials (RCTs) and other clinical efficacy models. Researchers examined patient-reported outcomes describing perceived discomfort related to nasal symptoms like sneezing, runny nose (rhinorrhea), and nasal stuffiness, as well as ocular symptoms like itching and watering.

Findings describe patterns observed in the studies related to how symptom scores evolved in the observed populations during periods of increased symptom activity. The evidence, which includes years of clinical experience and confirmatory trials, contributes to the broader evidence landscape for this type of medication.

Evidence for Use in Urticaria (Hives) and Mild Allergic Skin Reactions

Research explored Marsthine in studies relevant to allergic skin manifestations such as urticaria (hives) and associated mild swelling. Studies explored outcomes related to physical discomfort, focusing on measurements of pruritus (itching) and the characteristics of wheal formation. The evidence here is supported by clinical efficacy trials and historical data derived from observational settings evaluating daily-life functioning when symptoms are acute.

Long-Term Studies and Follow-up Duration

The majority of research for Marsthine that explores short-term symptom changes has follow-up durations that were limited. Studies were largely conducted during periods of increased symptom activity and reported outcomes measured over short time intervals, such as a few days of treatment or observation for up to 12 hours post-dose.

There is limited information for long-term outcomes and the sustained nature of observed symptom patterns beyond short-term use. Long-term effects are not fully established in the literature for this specific drug, and evidence is limited regarding patterns of use and outcomes over extended periods of time or for chronic management.

What is Still Uncertain About Marsthine's Evidence Base

Limited information exists regarding long-term outcomes and the sustained patterns of symptom changes beyond short-term use. Follow-up durations were limited in many of the core efficacy studies.

Additionally, comparative evidence is lacking, as there are few recent, large-scale studies that directly compare the findings of Marsthine to subsequent generations of H1-antagonists. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Clemastine (Oral Route) Uses and Indications

Frequently Asked Questions (FAQ)

Common questions about Marsthine (FAQ)


Q: How quickly should I expect to feel the effects of Marsthine?

Studies and official information indicate that the concentration of Marsthine in the bloodstream typically peaks within 2 to 4 hours after taking a dose. The documented antihistaminic activity has been shown to reach its peak benefit between 5 and 7 hours post-dose.


Q: What's the typical time it takes for Marsthine to start working?

According to the official product information, peak concentrations in the plasma, or bloodstream, are generally reached 2 to 4 hours after administration. The drug’s main benefit of blocking histamine is shown to reach its peak between 5 and 7 hours after you take the dose.


Q: Does Marsthine need to be taken long-term?

Regulatory documents state that Marsthine is indicated for the temporary relief of symptoms associated with allergic conditions. It is typically used on an intermittent, as-needed basis for acute symptomatic relief and is not generally intended for continuous long-term maintenance.


Q: Is it normal to feel a bit nauseous when first starting Marsthine?

Nausea is listed in the official product information as an uncommon or rare side effect associated with the use of Marsthine. A very common side effect, especially at the start of treatment, is sedation, or drowsiness.


Q: Does Marsthine affect sleep?

Marsthine is associated with effects on the central nervous system, including sleep. Sedation, which causes drowsiness, is the most common side effect. In children, official documents note that paradoxical excitation, which can include symptoms like insomnia or restlessness, may occur.


Q: Does Marsthine interact with birth control pills?

The official prescribing information does not document any specific interactions with Marsthine that significantly modify its plasma exposure, or the level of the drug in the bloodstream. The official prescribing information does not document any known effect on the absorption or metabolism of oral contraceptives.


Q: Can Marsthine be used while breastfeeding?

Regulatory documents strictly contraindicate the use of Marsthine in nursing mothers. This prohibition is based on the documented potential for adverse reactions in the infant.


Q: Can Marsthine cause changes in mood or behavior?

Official information notes several adverse reactions related to the nervous system, including fatigue, confusion, restlessness, and nervousness. In pediatric patients, a reaction called paradoxical excitation may occur, characterized by nervousness or restlessness, which can be seen as a change in behavior or mood.


Q: Does taking Marsthine make you more sensitive to the sun?

Increased sensitivity of the skin to the sun, known as photosensitivity, has been reported with antihistamines like Marsthine. If you are concerned about sun exposure, you may wish to discuss this risk with a healthcare provider.


Q: Can Marsthine affect blood pressure?

Marsthine must be used with caution in patients who have pre-existing cardiovascular disease or high blood pressure (hypertension). Additionally, in older adults, there is a documented increased risk of low blood pressure (hypotension).


Q: Are there specific foods I should avoid while on Marsthine?

The official labeling explicitly advises against the consumption of alcoholic beverages while taking this medicine. No specific foods are mandated for avoidance in the prescribing information.


Q: How is Marsthine processed by the liver or kidneys?

According to the official product information, Marsthine is primarily metabolized, or broken down, in the liver. Urinary excretion is documented as the major way the drug is eliminated from the body. Official guidance indicates that lower doses may be considered for patients with liver impairment.


Q: Is Marsthine safe to take during pregnancy?

Marsthine is classified by the FDA as Pregnancy Category B. This classification means that while animal studies have not demonstrated a risk to the fetus, there are no adequate and well-controlled studies conducted in pregnant women. Official documents state that its use during pregnancy is recommended only if clearly needed.


Q: How long does Marsthine stay in your system after stopping?

Studies of the drug’s effects show that antihistaminic activity has been documented to persist for 10 to 12 hours and, in some cases, for as long as 24 hours.


Q: Does Marsthine need to be taken with food?

The official prescribing information for Marsthine does not mandate that the drug must be taken with food for it to work properly. The drug is described as being rapidly absorbed from the gastrointestinal tract regardless of food intake.


Q: Are there any vitamins or supplements that interact badly with Marsthine?

The official prescribing information lists known, serious interactions with Monoamine Oxidase (MAO) Inhibitors, alcohol, and other CNS depressants. No specific vitamins or non-MAOI supplements are listed as mandatory for avoidance in the regulatory documents.


Q: What if Marsthine doesn't seem to be working for me after a few weeks?

Marsthine is intended for short-term, intermittent use to provide symptomatic relief. If allergy symptoms persist, worsen, or are not adequately relieved after a period of use, official documentation recommends consulting a healthcare professional.


Q: Are there different strengths or dosages of Marsthine?

Marsthine is manufactured in different presentations for oral use, including solid tablets and an oral solution. The official documents state the maximum total daily intake that is permitted in a 24-hour period.


Q: Can Marsthine be used if I have a history of heart problems?

Marsthine must be used with caution in patients with a history of cardiovascular disease, hypertension, or hyperthyroidism. Caution is specifically advised due to the risk of effects like tachycardia, or a rapid heartbeat.


Q: Is Marsthine habit-forming or addictive?

The official regulatory safety information for Marsthine does not describe the drug as having habit-forming or addictive potential.


Q: How long does the primary benefit of a single dose of Marsthine last?

The antihistaminic benefit from a single dose of Marsthine is documented to persist for 10 to 12 hours and, in some cases, for as long as 24 hours.


Q: Is Marsthine a targeted therapy?

Marsthine is officially classified as a first-generation H1-receptor antagonist. Its mechanism involves competitively blocking H1 receptors and muscarinic acetylcholine receptors throughout the body, but it is not formally described as a 'targeted therapy' in the regulatory labeling.


Q: Can Marsthine interact with herbal remedies like St. John's Wort?

The official prescribing information warns of specific interactions with alcohol, Monoamine Oxidase (MAO) inhibitors, and other CNS depressants. No specific herbal remedies, including St. John’s Wort, are listed in the regulatory documents for mandatory avoidance.

How should Marsthine be stored and disposed of?

How to Store and Dispose of Marsthine

Storage Requirements

Marsthine (Clemastine Fumarate) must be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), as defined in official labeling. The product must be stored in its tightly closed, original container and be protected from excess heat, direct sunlight, and moisture.

Child Safety and Handling

To ensure child safety, the medicine must be kept out of the sight and reach of children, and safety caps must be securely locked. Storage areas should be cool and dry, away from places like the bathroom where excess moisture is common.

Disposal Instructions

Unused or expired Marsthine should be disposed of by following specific instructions on the prescription drug labeling. The preferred method is using a drug take-back program or authorized collection site. If household disposal is necessary, the product must be mixed with an undesirable substance, sealed in a container, and identifying information on the label must be scratched out prior to discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Marsthine found in:

A-Z Index: